Search results
Showing 1 to 10 of 10 results for acitretin
This guideline covers assessing and managing psoriasis in adults, young people and children. It aims to improve long-term disease control and quality of life for people with psoriasis.
Certolizumab pegol for treating moderate to severe plaque psoriasis (TA574)
Evidence-based recommendations on certolizumab pegol (Cimzia) for treating moderate to severe plaque psoriasis in adults.
Spesolimab for treating generalised pustular psoriasis flares (TA1070)
Evidence-based recommendations on spesolimab (Spevigo) for treating generalised pustular psoriasis flares in adults.
Deucravacitinib for treating moderate to severe plaque psoriasis (TA907)
Evidence-based recommendations on deucravacitinib for treating moderate to severe plaque psoriasis in adults.
This quality standard covers assessing and managing psoriasis in adults, young people and children. It describes high-quality care in priority areas for improvement.
View quality statements for QS40Show all sections
Sections for QS40
- Quality statements
- Quality statement 1: Assessing disease severity
- Quality statement 2: Assessing impact of disease
- Quality statement 3: Referring to specialist services
- Quality statement 4: Assessing cardiovascular risk
- Quality statement 5: Assessing for psoriatic arthritis
- Quality statement 6: Monitoring systemic treatment
- Update information
Secukinumab for treating moderate to severe hidradenitis suppurativa (TA935)
Evidence-based recommendations on secukinumab (Cosentyx) for active moderate to severe hidradenitis suppurativa (acne inversa) in adults.
Brodalumab for treating moderate to severe plaque psoriasis (TA511)
Evidence-based recommendations on brodalumab (Kyntheum) for treating moderate to severe plaque psoriasis in adults.
Dimethyl fumarate for treating moderate to severe plaque psoriasis (TA475)
Evidence-based recommendations on dimethyl fumarate (Skilarence) for treating moderate to severe plaque psoriasis in adults.
Adalimumab for treating moderate to severe hidradenitis suppurativa (TA392)
Evidence-based recommendations on adalimumab (Humira) for treating active moderate to severe hidradenitis suppurativa in adults whose disease has not responded to conventional systemic therapy.
Tildrakizumab for treating moderate to severe plaque psoriasis (TA575)
Evidence-based recommendations on tildrakizumab (Ilumetri) for treating moderate to severe plaque psoriasis in adults.